Mattias Mattsson

Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years

Akin, Cem; Sabato, Vito; Gotlib, Jason; Panse, Jens et al.

Ingår i Journal of Allergy and Clinical Immunology, s. 421-431, 2026

• DOI för Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years
• Ladda ner fulltext (pdf) av Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia

Al-Sawaf, Othman; Stumpf, Janina; Zhang, Can; Simon, Florian et al.

Ingår i New England Journal of Medicine, s. 1084-1096, 2026

• DOI för Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia

ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker

Thorvaldsdottir, Birna; Mansouri, Larry; Sutton, Lesley-Ann; Nadeu, Ferran et al.

Ingår i Leukemia, s. 1650-1660, 2025

• DOI för ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker
• Ladda ner fulltext (pdf) av ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial

Niemann, Carsten U.; Dubois, Julie; Nasserinejad, Kazem; da Cunha-Bang, Caspar et al.

Ingår i Blood Advances, s. 3665-3675, 2025

• DOI för Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial
• Ladda ner fulltext (pdf) av Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial

Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis

Ruefer, Axel; Nilius, Henning; Hermine, Olivier; Niedoszytko, Marek et al.

Ingår i Leukemia, s. 675-683, 2025

• DOI för Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis
• Ladda ner fulltext (pdf) av Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis

Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years

Akin, Cem; Sabato, Vito; Gotlib, Jason; Panse, Jens et al.

Ingår i Journal of Allergy and Clinical Immunology, s. 421-431, 2026

• DOI för Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years
• Ladda ner fulltext (pdf) av Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia

Al-Sawaf, Othman; Stumpf, Janina; Zhang, Can; Simon, Florian et al.

Ingår i New England Journal of Medicine, s. 1084-1096, 2026

• DOI för Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia

ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker

Thorvaldsdottir, Birna; Mansouri, Larry; Sutton, Lesley-Ann; Nadeu, Ferran et al.

Ingår i Leukemia, s. 1650-1660, 2025

• DOI för ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker
• Ladda ner fulltext (pdf) av ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial

Niemann, Carsten U.; Dubois, Julie; Nasserinejad, Kazem; da Cunha-Bang, Caspar et al.

Ingår i Blood Advances, s. 3665-3675, 2025

• DOI för Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial
• Ladda ner fulltext (pdf) av Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial

Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis

Ruefer, Axel; Nilius, Henning; Hermine, Olivier; Niedoszytko, Marek et al.

Ingår i Leukemia, s. 675-683, 2025

• DOI för Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis
• Ladda ner fulltext (pdf) av Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis

Medical history and lifestyle factors have limited impact on time-to-first-treatment in patients with chronic lymphocytic leukemia

Glimelius, Ingrid; Kleinstern, Geffen; Robinson, Dennis P.; Mansouri, Larry et al.

Ingår i eJHaem, s. 998-1004, 2024

• DOI för Medical history and lifestyle factors have limited impact on time-to-first-treatment in patients with chronic lymphocytic leukemia
• Ladda ner fulltext (pdf) av Medical history and lifestyle factors have limited impact on time-to-first-treatment in patients with chronic lymphocytic leukemia

Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry

Niedoszytko, Marek; Gorska, Aleksandra; Brockow, Knut; Bonadonna, Patrizia et al.

Ingår i Allergy. European Journal of Allergy and Clinical Immunology, s. 2470-2481, 2024

• DOI för Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry

Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis

Iribarren, Cristina; Levedahl, Kerstin; Atanasoai, Ionut; Mattsson, Mattias et al.

Ingår i Journal of Molecular Diagnostics, s. 792-804, 2024

• DOI för Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis
• Ladda ner fulltext (pdf) av Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis

Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM

Lübke, Johannes; Schmid, Alicia; Christen, Deborah; Elberink, Hanneke N. G. Oude et al.

Ingår i Blood Advances, s. 2890-2900, 2024

• DOI för Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM
• Ladda ner fulltext (pdf) av Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM

Avapritinib versus Placebo in Indolent Systemic Mastocytosis

Gotlib, Jason; Castells, Mariana; Elberink, Hanneke Oude; Siebenhaar, Frank et al.

Ingår i NEJM EVIDENCE, 2023

• DOI för Avapritinib versus Placebo in Indolent Systemic Mastocytosis

Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry

Kennedy, Vanessa E.; Perkins, Cecelia; Reiter, Andreas; Jawhar, Mohamad et al.

Ingår i Blood Advances, s. 1713-1724, 2023

• DOI för Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry

Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

Mansouri, Larry; Thorvaldsdottir, Birna; Sutton, Lesley-Ann; Karakatsoulis, Georgios et al.

Ingår i Leukemia, s. 339-347, 2023

• DOI för Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY
• Ladda ner fulltext (pdf) av Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis

Lübke, Johannes; Schwaab, Juliana; Christen, Deborah; Elberink, Hanneke Oude et al.

Ingår i Journal of Allergy and Clinical Immunology, s. 581-590, 2023

• DOI för Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis

Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature

Del Giudice, Ilaria; Cappelli, Luca Vincenzo; Delgado, Julio; Niemann, Carsten Utoft et al.

Ingår i British Journal of Haematology, s. 353-356, 2023

• DOI för Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial

Kater, Arnon P.; Levin, Mark-David; Dubois, Julie; Kersting, Sabina et al.

Ingår i The Lancet Oncology, s. 818-828, 2022

Cardiovascular disease in patients with chronic lymphocytic leukemia: A Swedish nationwide register study with matched comparators

Larsson, Karin; Soderling, Jonas; Höglund, Martin; Glimelius, Ingrid et al.

Ingår i American Journal of Hematology, 2022

• DOI för Cardiovascular disease in patients with chronic lymphocytic leukemia: A Swedish nationwide register study with matched comparators

Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?

Brieghel, Christian; Galle, Veerle; Agius, Rudi; Da Cunha-Bang, Caspar et al.

Ingår i European Journal of Haematology, s. 369-378, 2022

• DOI för Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?
• Ladda ner fulltext (pdf) av Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?

Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis

Zanotti, Roberta; Bonifacio, Massimiliano; Lucchini, Giuseppe; Sperr, Wolfgang R. et al.

Ingår i Leukemia, s. 516-524, 2022

• DOI för Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis

Five Percent Variant Allele Frequency Is a Reliable Reporting Threshold for TP53 Variants Detected by Next Generation Sequencing in Chronic Lymphocytic Leukemia in the Clinical Setting

Pandzic, Tatjana; Ladenvall, Claes; Engvall, Marie; Mattsson, Mattias et al.

Ingår i HemaSphere, 2022

• DOI för Five Percent Variant Allele Frequency Is a Reliable Reporting Threshold for TP53 Variants Detected by Next Generation Sequencing in Chronic Lymphocytic Leukemia in the Clinical Setting
• Ladda ner fulltext (pdf) av Five Percent Variant Allele Frequency Is a Reliable Reporting Threshold for TP53 Variants Detected by Next Generation Sequencing in Chronic Lymphocytic Leukemia in the Clinical Setting

Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis

Kluin-Nelemans, Hanneke C.; Jawhar, Mohamad; Reiter, Andreas; van Anrooij, Bjorn et al.

Ingår i Theranostics, s. 292-303, 2021

• DOI för Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis
• Ladda ner fulltext (pdf) av Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis

Assessing Patients' Knowledge on Chronic Lymphocytic Leukemia: Validation of the ERIC CLL Knowledge Questionnaire in Greece

Karamanidou, Christina; Xochelli, Aliki; Papaioannou, Maria; Moysiadis, Theodoros et al.

Ingår i HemaSphere, 2021

• DOI för Assessing Patients' Knowledge on Chronic Lymphocytic Leukemia: Validation of the ERIC CLL Knowledge Questionnaire in Greece

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Chatzikonstantinou, Thomas; Kapetanakis, Anargyros; Scarfò, Lydia; Karakatsoulis, Georgios et al.

Ingår i Leukemia, s. 3444-3454, 2021

• DOI för COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
• Ladda ner fulltext (pdf) av COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib

Svanberg, Rebecka; Ostrowski, Sisse Rye; Nasserinejad, Kazem; Kersting, Sabina et al.

Ingår i Leukemia and Lymphoma, s. 3422-3431, 2020

• DOI för Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib

High prevalence and incidence of cardiovascular disease in chronic lymphocytic leukaemia: a nationwide population-based study

Larsson, Karin; Mattsson, Mattias; Ebrahim, Fereshte; Glimelius, Ingrid et al.

Ingår i British Journal of Haematology, 2020

• DOI för High prevalence and incidence of cardiovascular disease in chronic lymphocytic leukaemia: a nationwide population-based study

Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations

Levin, Mark-David; Kater, Arnon P.; Mattsson, Mattias; Kersting, Sabina et al.

Ingår i BMJ Open, 2020

• DOI för Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations
• Ladda ner fulltext (pdf) av Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations

Increasing prevalence of chronic lymphocytic leukemia with an estimated future rise: a nationwide population-based study

Mattsson, Mattias; Sandin, Fredrik; Kimby, Eva; Höglund, Martin et al.

Ingår i American Journal of Hematology, 2020

• DOI för Increasing prevalence of chronic lymphocytic leukemia with an estimated future rise: a nationwide population-based study

5-year Follow up After MSC-based Treatment of Severe Acute Respiratory Distress Syndrome

Simonson, Oscar; Ståhle, Elisabeth; Hansen, Tomas; Wedin, Johan O et al.

Ingår i American Journal of Respiratory and Critical Care Medicine, s. 1051-1055, 2020

• DOI för 5-year Follow up After MSC-based Treatment of Severe Acute Respiratory Distress Syndrome
• Ladda ner fulltext (pdf) av 5-year Follow up After MSC-based Treatment of Severe Acute Respiratory Distress Syndrome

Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification

Trizuljak, Jakub; Sperr, Wolfgang R.; Nekvindova, Lucie; Elberink, Hanneke O. et al.

Ingår i Allergy. European Journal of Allergy and Clinical Immunology, s. 1927-1938, 2020

• DOI för Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification

International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia

Condoluci, Adalgisa; di Bergamo, Lodovico Terzi; Langerbeins, Petra; Hoechstetter, Manuela A. et al.

Ingår i Blood, s. 1859-1869, 2020

• DOI för International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia

The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome

Brieghel, Christian; da Cunha-Bang, Caspar; Yde, Christina Westmose; Schmidt, Ane Yde et al.

Ingår i Clinical Cancer Research, s. 1507-1515, 2020

• DOI för The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome

Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry

Kluin-Nelemans, Hanneke C.; Reiter, Andreas; Illerhaus, Anja; van Anrooij, Bjorn et al.

Ingår i Leukemia, s. 1090-1101, 2020

• DOI för Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry

Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia

Baliakas, Panagiotis; Moysiadis, Theodoros; Hadzidimitriou, Anastasia; Xochelli, Aliki et al.

Ingår i Haematologica, s. 360-369, 2019

• DOI för Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia
• Ladda ner fulltext (pdf) av Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia

Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis

Grootens, Jennine; Ungerstedt, Johanna S.; Ekoff, Maria; Rönnberg, Elin et al.

Ingår i EBioMedicine, s. 150-158, 2019

• DOI för Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis
• Ladda ner fulltext (pdf) av Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis

Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort

Winqvist, Maria; Andersson, Per-Ola; Asklid, Anna; Karlsson, Karin et al.

Ingår i Haematologica, 2019

• DOI för Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort
• Ladda ner fulltext (pdf) av Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort

First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013

Sylvan, Sandra Eketorp; Asklid, Anna; Johansson, Hemming; Klintman, Jenny et al.

Ingår i Haematologica, s. 797-805, 2019

• DOI för First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013

No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy

Baliakas, Panagiotis; Mattsson, Mattias; Hadzidimitriou, Anastasia; Minga, Eva et al.

Ingår i Haematologica, 2018

• DOI för No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy

Serological reactivity to Anaplasma phagocytophilum in neoehrlichiosis patients

Wass, Linda; Grankvist, Anna; Mattsson, Mattias; Gustafsson, Helena et al.

Ingår i European Journal of Clinical Microbiology and Infectious Diseases, s. 1673-1678, 2018

• DOI för Serological reactivity to Anaplasma phagocytophilum in neoehrlichiosis patients
• Ladda ner fulltext (pdf) av Serological reactivity to Anaplasma phagocytophilum in neoehrlichiosis patients

Continuous Increasing Prevalence of Chronic Lymphocytic Leukemia (CLL) with an Estimated Future Rise-a Nationwide Population-Based Study from Sweden

Mattsson, Mattias; Sandin, Fredrik; Kimby, Eva; Höglund, Martin et al.

Ingår i Blood, 2018

• DOI för Continuous Increasing Prevalence of Chronic Lymphocytic Leukemia (CLL) with an Estimated Future Rise-a Nationwide Population-Based Study from Sweden

Spontaneous Clinical Regression In Chronic Lymphocytic Leukemia: Clinical And Biologic Features Of 9 Cases From The ERIC Registry

Del Giudice, I.; Visentin, A.; Trentin, L.; Flogegard, M. et al.

Ingår i Haematologica, s. 121-122, 2017

Spontaneous Clinical Regression In Chronic Lymphocytic Leukemia: Clinical And Biologic Features Of 9 Cases From The ERIC Registry

Del Giudice, I.; Visentin, A.; Trentin, L.; Flogegard, M. et al.

Ingår i Haematologica, s. 714-714, 2017

Is FCR the treatment of choice for IGHV mutated CLL without poor FISH cytogenetics?

Baliakas, Panagiotis; Moreno, Carol; Cuellar, Carolina; Scarfo, Lydia et al.

Ingår i Leukemia and Lymphoma, s. 170-171, 2017

• DOI för Is FCR the treatment of choice for IGHV mutated CLL without poor FISH cytogenetics?

Natural IgM antibodies in the immune defence against neoehrlichiosis

Wennerås, Christine; Goldblatt, David; Zancolli, Marta; Mattsson, Mattias et al.

Ingår i Infectious Diseases, s. 809-816, 2017

• DOI för Natural IgM antibodies in the immune defence against neoehrlichiosis

Prognostic impact of epigenetic classification in chronic lymphocytic leukemia: The case of subset #2

Bhoi, Sujata; Ljungström, Viktor; Baliakas, Panagiotis; Mattsson, Mattias et al.

Ingår i Epigenetics, s. 449-455, 2016

• DOI för Prognostic impact of epigenetic classification in chronic lymphocytic leukemia: The case of subset #2

No Improvement In Long-Term Overall Survival After The Introduction Of Chemo(Immuno)Therapy For Chronic Lymphocytic Leukemia Patients Belonging To Stereotyped Subset #2

Baliakas, Panagiotis; Mattsson, Mattias; Hadzidimitriou, A.; Minga, E. et al.

Ingår i Haematologica, s. 231-231, 2016

UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?

Bhoi, Sujata; Baliakas, Panagiotis; Cortese, Diego; Mattsson, Mattias et al.

Ingår i Haematologica, 2016

• DOI för UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.

Winqvist, Maria; Asklid, Anna; Andersson, P O; Karlsson, Karin et al.

Ingår i Haematologica, s. 1573-1580, 2016

• DOI för Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.

Ex Vivo Lymph Node Native Microenvironment Assay Shows Novel Antiproliferative Activity For Idelalisib And Ibrutinib On Cll Cells

Ballesteros, J.; Scarfo, L.; Mattsson, Mattias; Xochelli, A. et al.

Ingår i Haematologica, s. 426-426, 2016

Personalized Modeling of Disease Evolution in CLL: Does Statistical Significance Translate into Predictive Accuracy?

Chatzilari, Elisavet; Baliakas, Panagiotis; Xochelli, Aliki; Maronidis, Anastasios et al.

Ingår i Blood, 2015

Personalized Modeling of Disease Evolution in CLL: Does Statistical Significance Translate into Predictive Accuracy?

Chatzilari, Elisavet; Baliakas, Panagiotis; Xochelli, Aliki; Maronidis, Anastasios et al.

Ingår i Blood, 2015

REFINING PROGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH SOMATICALLY HYPERMUTATED B-CELL RECEPTORS: A NOVEL PROGNOSTIC INDEX ON BEHALF OF THE EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC)

Baliakas, Panagiotis; Hadzidimitriou, A.; Mattsson, Mattias; Xochelli, Aliki et al.

Ingår i Haematologica, s. 52-52, 2015

In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome

Simonson, Oscar E.; Mougiakakos, Dimitrios; Heldring, Nina; Bassi, Giulio et al.

Ingår i Stem Cells Translational Medicine, s. 1199-1213, 2015

• DOI för In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome

Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program

Hansson, Lotta; Winqvist, Maria; Asklid, Anna; Andersson, P-O et al.

Ingår i Blood, 2015

An Innovative High-Throughput Ex Vivo Drug Assay Incorporating the Native Microenvironment Reveals a Novel Mechanism of Action of Idelalisib in CLL

Ballesteros, Joan; Scarfo, Lydia; Mattsson, Mattias; Xochelli, Aliki et al.

Ingår i Blood, 2015

First report from the Swedish CLL-registry: a nationwide registry with high coverage

Kimby, Eva; Abrahamsson, Marie; Mattsson, Mattias

Ingår i Leukemia and Lymphoma, s. 42-42, 2015

Clonal evolution patterns in high-risk chronic lymphocytic leukemia treated with ibrutinib

Mattsson, Mattias; Ljungström, Viktor; Djureinovic, Tatjana; Mansouri, Larry et al.

The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives

Valent, Peter; Elberink, Joanna N. G. Oude; Gorska, Aleksandra; Lange, Magdalena et al.

Ingår i Journal of Allergy and Clinical Immunology, s. 81-87, 2019

• DOI för The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives

Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed?

Baliakas, Panagiotis; Mattsson, Mattias; Stamatopoulos, Kostas; Rosenquist Brandell, Richard

Ingår i Journal of Internal Medicine, s. 347-357, 2016

• DOI för Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed?

Chronic lymphocytic leukemia: Studies from genetics to epidemiology with focus on the impact of different treatments

Mattsson, Mattias

2020

• Ladda ner fulltext (pdf) av Chronic lymphocytic leukemia: Studies from genetics to epidemiology with focus on the impact of different treatments

BTK-inhibitors: Focus on Ibrutinib and similar Agents

Mattsson, Mattias; Scarfo, Lydia

Ingår i Resistance of targeted therapies excluding antibodies for lymphomas, Springer, 2018

• DOI för BTK-inhibitors: Focus on Ibrutinib and similar Agents

Isolated subclonal mutations are not a common feature in untreated chronic lymphocytic leukemia

Larsson, Karin; Young, Emma; Höglund, Martin; Mattsson, Mattias et al.

Population-based incidence, prevalence and survival of systemic AL amyloidosis in Sweden

Rosengren, Sara; Thelander, Ulrika; Mattsson, Mattias; Carlson, Kristina